Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice

International Journal of Oncology

Volumn 13, Issue 3, 1998, Pages 429-435

  Lamharzi, Najib ^a   Halmos, Gábor ^a   Jungwirth, Andreas ^a,c   Schally, Andrew V ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c St Johanns Spital   (Austria)

Author keywords

Androgen independent prostate cancer; LH RH antagonist; RT PCR; Southern blotting

Indexed keywords

CETRORELIX; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GONADORELIN RECEPTOR; MESSENGER RNA; TRIPTORELIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECEPTOR AFFINITY; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR XENOGRAFT;

EID: 0031876636     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.3.429     Document Type: Article

References (43)

1. Clayton RN: Gonadotropin-releasing hormone: its actions and receptors. J Endocrinol 120: 9-11, 1989.
2. Qayum A, Gullick W, Clayton RC, Sikora K and Waxman J: The effects of gonadotropin hormone analogues in prostate cancer are mediated through specific tumor receptors. Br J Cancer 62: 96-99, 1990.
3. Schally AV and Comaru-Schally AM: Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynæcologic conditions. Adv Drug Deliv Rev 28: 157-169, 1997.
4. Schally AV and Comaru-Schally AM: Hypothalamic and other peptide hormones. In: Cancer Medicine 4M. Holland JF, Frei E, Bast RC, Kufe DW, Morton DL and Weichselbaum RR (eds). Williams & Williams, Baltimore, MD, pp1067-1086, 1997.
5. Srkalovic G, Bokser L, Radulovic S, Korkut E and Schally AV: Receptors for luteinizing hormone-releasing hormone (LH-RH) in Dunning R-3327 prostate cancers and rats anterior pituitaries after treatment with a sustained delivery system of LH-RH antagonist SB-75. Endocrinology 127: 3052-3060, 1990.
6. Perheentupa A and Huhtaniemi I: Gonadotropin gene expression and secretion in gonadotropin-releasing hormone antagonisttreated male rats: effects of sex steroid replacement. Endocrinology 126: 3204-3209, 1990.
7. Bokser I, Srkalovic G, Szepeshazi K and Schally AV: Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone. Neuroendocrinology 54: 136-145, 1991.
8. Pinski J, Yano T, Groot K, Milovanovic S and Schally AV: Comparison of biological effects of a sustained delivery system and noncapsulated LH-RH antagonist SB-75 in rats. Peptides 13: 905-911, 1992.
9. Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M and Groot K: Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc Natl Acad Sci USA 93: 2398-2402, 1996.
10. Kaiser UB, Jakubowiak A, Stainberger A and Chin WW: Regulation of rat gonadotropin-releasing hormone receptor mRNA levels in vivo and in vitro. Endocrinology 133: 931-934, 1993.
11. Lerrant Y, Kottler ML, Bergametti F, Moumni M, Blumberg-Tick J and Counis R: Expression of gonadotropin-releasing hormone (GnRH) receptor gene is altered by GnRH agonist desensitization in a manner similar to that of gonadotropin β-subunit genes and castrated rat pituitary. Endocrinology 136: 2803-2808, 1995.
12. Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, Kakar SS and Schally AV: Chronic administration of the luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix decreases gonadotrope responsiveness and pituitary LH-RH receptor messenger ribonucleic acid levels in rats. Endocrinology 137: 3430-3436, 1996.
13. Wu JC, Sealfon SC and Miller WL: Gonadal hormones and gonadotropin-releasing hormone (GnRH) alter messenger ribonucleic acid levels for GnRH receptors in sheep. Endocrinology 134: 1846-1850, 1994.
14. Emons G, Ortmann O, Schulz K-D and Schally AV: Growth-inhibitory actions of analogues of luteinizing hormone-releasing hormone on tumor cells. Trends Endocrinol Metab 8: 355-362, 1997.
15. Gonzales-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, Fuentes-Garcia M, Cardenas-Cornejo I, Graef-Sanchez A, Comaru-Schally AM and Schally AV: Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia (BPH) and prostatic cancer. Prostate 24: 84-92, 1994.
16. Gonzalez-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, Fuentes-Garcia M, Cardenas-Cornejo I, Comaru-Schally AM and Schally AV: LH-RH antagonist SB-75 (Cetrorelix) as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 45: 275-281, 1995.
17. Behre H, Kliesch S, Pühse G, Reissmann T and Nieschlag E: High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men. J Clin Endocrinol Metab 82: 1403-1408, 1997.
18. Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai R-Z, Groot K, Vadillo-Buenfil M and Schally AV: Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 7: 1141-1148, 1997.
19. Halmos G and Schally AV: Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonists RC-3095. Proc Natl Acad Sci USA 94: 956-960, 1997.
20. Munson PJ and Rodbard DA: A versatile computerized approach for characterization of ligand binding system. Anal Biochem 107: 220-239, 1980.
21. Kakar SS, Musgrove LC, Devor CD, Sellers JC and Neill ND: Cloning, sequencing and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun 189: 289-295, 1992.
22. Xu Y-H, Richert N, Ito S, Merlino GT and Pastan I: Characterization of epidermal growth factor receptor gene expression in malignant and normal cell lines. Proc Natl Acad Sci USA 81: 7308-7313, 1984.
23. Gordon AW, Pegues PC, Johnson GR, Kannan B, Auesperg N and Stromberg K: mRNA phenotyping of the major ligands and receptors of the EGF superfamily in human ovarian epithelial cells. Cancer Lett 89: 63-71, 1995.
24. Mason DR, Arora KK, Mertz LM and Catt KJ: Homologous down-regulation of gonadotropin-releasing hormone receptor sites and messenger ribonucleic acid transcripts in αT3-1 cells. Endocrinology 135: 1165-1170, 1994.
25. Kakar S, Nath S, Bunn J and Jennes L: The inhibition of growth and down-regulation of gonadotropin releasing hormone (GnRH) receptor in αT3-1 cells by GnRH agonist. Anti-Cancer Drugs 8: 369-375, 1997.
26. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone (LH-RH) agonists on the human androgen-independent prostate cancer cell line DU-145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 54: 4091-4095, 1994.
27. Moretti MR, Marelli MM, Dondi D, Poletti L, Martini L, Motta M and Limonta P: Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU-145. J Clin Endocrinol Met 81: 3930-3937, 1996.
28. Irmer G, Bürger C, Müller R, Ortmann O, Peter U, Kakar S, Neill J, Schulz K-D and Emons G: Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LH-RH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 55: 817-822, 1995.
29. Jungwirth A, Galvan G, Pinski Y, Halmos G, Szepeshazi K, Cai R-Z, Groot K and Schally AV: Luteinizing hormone-releasing hormone antagonist Cetrorelix and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate 32: 164-172, 1997.
30. Shirahige Y, Cook CB, Pinski J, Halmos G, Nair R and Schally AV: Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice. Int J Oncol 5: 1031-1035, 1994.
31. MacDonald A and Habib FK: Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 651: 177-182, 1992.
32. Schuurmans ALG, Bolt J and Mulder E: Androgens stimulate both growth rate and epidermal growth factor receptor activity of the prostate tumor cell LNCaP. Prostate 12: 55-63, 1988.
33. Berns EMJJ, deBoer W and Mulder E: Androgen-dependent growth regulation and the release of specific proteins by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 9: 247-259, 1983.
34. Henttu P, Liao S and Vihko P: Androgen up-regulate the human prostate specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 130: 766-772, 1992.
35. Liu X-U, Wiley HS and Meikle AW: Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-α (TGF-α) and epidermal growth factor (EGF)/TGF-α receptor. J Clin Endocrinol Metab 77: 1472-1478, 1993.
36. Hazum E, Cuatrecasas P, Marian J and Conn PM: Receptor-mediated internalization of fluorescent gonadotropin-releasing hormone by pituitary gonadotropes. Proc Natl Acad Sci USA 77: 6692-6695, 1980.
37. Pelletier G, Dubé D, Guy J, Séguin C and Lefebvre FA: Binding and internalization of a luteinizing hormone-releasing hormone agonist by rat gonadotrophic cells. A radioautographic study. Endocrinology 111: 1068-1076, 1982.
38. Conn PM: The molecular basis of gonadotropin-releasing hormone action. Endocr Rev 7: 3-10, 1986.
39. Hazum E and Conn PM: Molecular mechanism of gonadotropin-releasing hormone (GnRH) action. I. The GnRH receptor. Endocr Rev 9: 379-386, 1988.
40. Rosner MR: Regulation of the epidermal growth factor receptor by growth modulating agents. Biotech Appl Biochem 12: 473-477, 1990.
41. Ewing TM, Murphy LJ and Ng M-L: Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer 44: 744-752, 1989.
42. Bertics PJ, Weber W, Cochet C, Pang GYN, Lee CSL, Watts KW and Sutherland RL: Regulation of the epidermal growth factor receptor by phosphorylation. J Cell Biochem 29: 195-208, 1985.
43. Lund KA, Lazar CS, Chen WS, Walsh BJ, Welsh JB, Herbst JJ, Walton GM, Rosenfeld MG, Gill GN and Wiley HS: Phosphorylation of the epidermal growth factor receptor threonine 654 inhibits ligand-induced internalization and down-regulation. J Biol Chem 265: 20517-20523, 1990.